$200M+ Revenue Automotive Supplier Acquisition Announced by Aspire Biopharma
Summary
Aspire Biopharma Holdings, Inc. (ASBP), a biopharmaceutical company with a $2.7 million market cap, has entered into a non-binding Letter of Intent (LOI) to acquire Dura Driver Control Systems (DCS), an automotive supplier reporting over $200 million in 2025 revenue and $20 million+ in Adjusted EBITDA for $30 million in cash. While an LOI for 'Driver Controls Systems' was announced yesterday via an 8-K and news release, this update provides crucial financial details of the target, revealing its significant scale. This represents an extraordinary strategic pivot for ASBP, moving from biopharmaceuticals to automotive manufacturing, and follows recent negative news including an amended 10-K citing going concern issues and a highly dilutive S-1/A filing. The acquisition, if completed, would be extraordinarily transformative, with the target's revenue dwarfing ASBP's current market valuation. Investors will be closely watching for the finalization of a definitive agreement, details on financing the $30 million cash purchase, and the strategic rationale for such a dramatic business model change.
At the time of this announcement, ASBP was trading at $0.54 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $0.52 to $35.01. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Access Newswire.